This week in therapeutics




Licensing status

Publication and contact information


Colon cancer


Mouse and cell culture studies suggest gain-of-function mutations in p53 can raise colorectal cancer risk by increasing susceptibility to chronic inflammation. In mouse intestinal epithelial cells, expression of a gain-of-function mutant p53 prolonged the inflammatory response to tumor necrosis factor-a (TNF-a) compared with expression of wild-type p53. In mice, expression of the p53 mutant increased susceptibility to chronic inflammation-induced colon cancer compared with expression of wild-type p53. Next steps could include confirming the association between mutant p53, colon cancer and chronic inflammation in additional models.

At least six companies have compounds that target p53 signaling in Phase II or earlier testing to treat various cancers.

SciBX 6(23); doi:10.1038/scibx.2013.575
Published online June 13, 2013

Patent and licensing status unavailable

Cooks, T. et al. Cancer Cell; published online May 13, 2013;
Contact: Moshe Oren, Weizmann Institute of Science, Rehovot, Israel